



Tatva Chintan Pharma Chem Ltd.

IPO DETAILS



Issue Opens

16th July 21, Fri

Issue Closes

20th July 21, Tue

Min. Lot Size

13 Shares

Issue Price Band

₹1,073 - ₹1,083

Issue size

Fresh Issue:
2.08 Mn Equity Shares
(₹2,250 Mn)

OFS:
2.54 Mn Equity Shares
(₹2,750 Mn)

Face Value

₹10

Listing at

NSE, BSE

Objectives of the Issue

Funding capital expenditure requirements for expansion of Dahej manufacturing facility and for upgrading R&D facilities in Vadodara.

To meet general corporate purposes.

Rating

SUBSCRIBE

APPLY NOW




Tatva Chintan Pharma Chem Ltd.

Company Overview

Tatva Chintan Pharma Chem Ltd. is a chemical manufacturing company that produces structure-directing agents (SDAs), phase transfer catalyst (PTCs), electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates alongside other specialty chemicals.



Industries they Serve



Industry Authority

- It is the largest and only commercial manufacturer of SDAs for zeolites in India.
- It is one of the leading global producers of an entire range of PTCs in India.




Company's facilities

- Two manufacturing facilities strategically located at Ankleshwar and Dahej in Gujarat.
- A dedicated research & development facility at Vadodara, Gujarat.




Tatva Chintan Pharma Chem Ltd.


Issue Details



Shareholding Pattern



Capital Structure (in ₹)



400 Mn

Authorised Equity Share Capital



201 Mn

Paid-Up Capital (Pre-Offer)



222 Mn

Paid-Up Capital (Post-Offer)




Tatva Chintan Pharma Chem Ltd.

Valuations and Peer Comparison


Market Cap
₹24,005 Mn

Adjusted EPS
23.76
post issue basis



Financial Snapshot (in Mn ₹)

- Revenue
- Total Income
- Total Expenses





Tatva Chintan Pharma Chem Ltd.

Business Insights



Competitive Strengths

- Leading manufacturer of structure directing agents and phase transfer catalysts, with consistent quality.
- Global presence with a wide customer base across various industries having high entry barriers.
- Modern manufacturing facilities with a focus on 'green' chemistry processes.
- Diversified specialized product portfolio requiring strong technical know-how.
- Strong R&D capabilities.



Business Strategy

- Expand existing product portfolio.
- Further develop R&D capabilities.
- Increase wallet share with existing customers and continued focus to expand customer base.
- Expand existing manufacturing capacities to capitalize on industry opportunities.



Risks

- Dependence on limited number of suppliers for certain raw materials. The loss of one or more such suppliers could adversely affect the business.
- Top 10 customers contributed a major chunk of revenue from operations in F.Y. 2021, 2020, and 2019 with ₹1,801.74 million (59.99%), ₹1,538.47 million (58.44%) and ₹969.37 million (46.99%) respectively.

Promoters and Management Details

Chintan Nitinkumar Shah - Managing Director